MedPath
HSA Approval

STESOLID ENEMA 5 mg/2.5 ml

SIN02309P

STESOLID ENEMA 5 mg/2.5 ml

STESOLID ENEMA 5 mg/2.5 ml

August 30, 1988

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.
Licence HolderTEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

ENEMA

**Dosage** Adult:10 – 20 mgChildren6 – 12 years of age:10 mg1 – 5 years of age:5 mg The dosage may be repeated if necessary.

RECTAL

Medical Information

**Indications** Stesolid rectal tubes are particularly well suited in the treatment of convulsion, including febrile convulsions in children, where the rapid onset of action is imperative.

**Contraindications** Myasthenia gravis

N05BA01

diazepam

Manufacturer Information

TEVA PHARMACEUTICAL INVESTMENTS SINGAPORE PTE. LTD.

PT Actavis Indonesia

Active Ingredients

DIAZEPAM

5 mg/2.5 ml

Diazepam

Documents

Package Inserts

STESOLID ENEMA 5mg 2.5ml PI.pdf

Approved: February 9, 2021

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.